-$0.43 EPS Expected for Molecular Templates, Inc. (NASDAQ:MTEM) This Quarter

Analysts predict that Molecular Templates, Inc. (NASDAQ:MTEMGet Rating) will post ($0.43) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Molecular Templates’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.39). Molecular Templates reported earnings per share of ($0.28) in the same quarter last year, which suggests a negative year-over-year growth rate of 53.6%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Molecular Templates will report full-year earnings of ($1.62) per share for the current financial year, with EPS estimates ranging from ($1.92) to ($1.33). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.71) per share, with EPS estimates ranging from ($2.16) to ($1.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Molecular Templates.

Molecular Templates (NASDAQ:MTEMGet Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. Molecular Templates had a negative return on equity of 110.16% and a negative net margin of 177.06%. The company had revenue of $8.49 million during the quarter, compared to the consensus estimate of $6.88 million.

A number of research analysts have recently weighed in on the company. Zacks Investment Research upgraded Molecular Templates from a “sell” rating to a “hold” rating in a research report on Friday, March 25th. Barclays dropped their price target on Molecular Templates from $8.00 to $4.50 and set an “overweight” rating for the company in a research report on Wednesday, March 30th. Bank of America cut Molecular Templates from a “buy” rating to an “underperform” rating and set a $1.50 price target for the company. in a research report on Friday, May 27th. Finally, Stifel Nicolaus dropped their price target on Molecular Templates from $11.00 to $9.00 in a research report on Friday, May 13th.

Shares of MTEM stock opened at $1.10 on Wednesday. Molecular Templates has a fifty-two week low of $0.88 and a fifty-two week high of $9.30. The stock has a market cap of $61.97 million, a P/E ratio of -0.80 and a beta of 1.61. The business has a fifty day simple moving average of $1.84 and a 200-day simple moving average of $2.76. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.75.

In related news, major shareholder Target N. V. Biotech acquired 200,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The stock was purchased at an average price of $1.18 per share, for a total transaction of $236,000.00. Following the transaction, the insider now owns 11,192,003 shares in the company, valued at approximately $13,206,563.54. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 28.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bellevue Group AG grew its holdings in Molecular Templates by 1.8% in the 1st quarter. Bellevue Group AG now owns 11,078,003 shares of the biotechnology company’s stock valued at $38,219,000 after buying an additional 200,000 shares during the period. BlackRock Inc. grew its holdings in Molecular Templates by 8.7% in the 4th quarter. BlackRock Inc. now owns 2,850,901 shares of the biotechnology company’s stock valued at $11,175,000 after buying an additional 228,321 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Molecular Templates in the 1st quarter valued at about $4,740,000. Adage Capital Partners GP L.L.C. grew its holdings in Molecular Templates by 18.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,000 shares of the biotechnology company’s stock valued at $4,704,000 after buying an additional 185,000 shares during the period. Finally, Kingdon Capital Management L.L.C. grew its holdings in Molecular Templates by 1.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,021,317 shares of the biotechnology company’s stock valued at $6,853,000 after buying an additional 9,822 shares during the period. Institutional investors own 88.72% of the company’s stock.

Molecular Templates Company Profile (Get Rating)

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.

Recommended Stories

Get a free copy of the Zacks research report on Molecular Templates (MTEM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Molecular Templates (NASDAQ:MTEM)

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.